Pharmaserv Logistics expands its service portfolio to include the storage of genetically modified organisms (GMOs)
Pharmaserv Logistics, a leading provider of specialized logistics solutions for the pharmaceutical and biotech industry, has expanded its service portfolio to include the sophisticated storage of genetically modified organisms (GMOs). This provides logistical support to a leading vaccine manufacturer and long-standing existing customer.
The decision to expand the portfolio was made against the background that Pharmaserv Logistics sees its strengths in the realization of customer-specific special logistics requirements. Manuel Sierra Garcia, the new Vice President of Pharmaserv Logistics, emphasizes: “Our many years of experience and expertise in the field of logistics for biologics have enabled us to implement this sophisticated warehouse solution.”
The active ingredient (drug substance) based on genetically modified and attenuated viruses and the lyophilized vaccine (drug product) are stored both in their final packaged form and unpackaged. Both substances must be stored in a specially converted room of safety level 1 according to GenTSV in the temperature ranges +2 to +8 °C and at -80 °C.
Pharmaserv Logistics has set up a separate storage area at the Behringwerke headquarters in Marburg to store this GMO material. This area meets the strict requirements regarding temperature control and regulatory specifications. These include the provision, risk assessment and operation of autoclaves to neutralize material, the establishment of an access-controlled area for trained personnel and the provision of personal protective equipment and disinfectants and hygiene products.
In addition, Pharmaserv Logistics will also carry out GDP-compliant transportation of drug substances and drug products along the customer's supply chain.